Stroke Medicine
University Hospital Zurich is involved in clinical research focused on acute ischemic stroke, with particular attention to preventing recurrent cerebrovascular events in patients without known atrial fibrillation at admission.
- Secondary stroke prevention
- Acute ischemic stroke
- Cerebrovascular recurrence
The research activity centres on identifying patients who may benefit from more targeted antithrombotic strategies after an initial ischemic event.
Thromboembolic Risk Assessment
The sponsor’s clinical interest includes using biomarker-based selection to refine the assessment of cardioembolic risk and guide post-stroke treatment decisions.
- Biomarker-guided selection
- Proatrial natriuretic peptide
- Occult atrial fibrillation
This area reflects a focus on patients whose underlying embolic source may not be evident at the time of stroke presentation.
Antithrombotic Therapy
Clinical research is directed toward comparing direct oral anticoagulants with standard antiplatelet therapy in the setting of stroke prevention after an ischemic event.
- Direct oral anticoagulants
- Antiplatelet therapy
- Recurrent stroke prevention
The therapeutic emphasis lies in determining which antithrombotic approach is most suitable for patients selected by biomarker profile.
Neurology and Vascular Care
The hospital’s research portfolio, as represented by the available trial activity, sits within neurology and vascular medicine, with collaboration across multiple research sites in Switzerland and beyond.
- Vascular neurology
- Multicentre collaboration
- Stroke recurrence prevention
Its clinical research interest is concentrated on improving care pathways for patients at risk of further ischemic events after stroke.